Current and historical daily PE Ratio for Laboratorios Farmaceuticos Rovi (
XMAD:ROVI
) from 2007 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Laboratorios Farmaceuticos Rovi stock (XMAD:ROVI) PE ratio as of Jun 04 2024 is 33.75.
More Details
Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) PE Ratio (TTM) Chart
Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1276
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Laboratorios Farmaceuticos Rovi PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-04 | 33.8 | 2024-03-28 | 30.8 |
| 2024-06-03 | 33.8 | 2024-03-27 | 24.9 |
| 2024-05-31 | 33.4 | 2024-03-26 | 24.7 |
| 2024-05-30 | 33.5 | 2024-03-25 | 24.8 |
| 2024-05-29 | 33.5 | 2024-03-22 | 24.6 |
| 2024-05-28 | 33.6 | 2024-03-21 | 24.3 |
| 2024-05-27 | 34.0 | 2024-03-20 | 24.3 |
| 2024-05-24 | 34.8 | 2024-03-19 | 24.5 |
| 2024-05-23 | 34.2 | 2024-03-18 | 24.3 |
| 2024-05-22 | 33.8 | 2024-03-15 | 23.9 |
| 2024-05-21 | 33.5 | 2024-03-14 | 24.1 |
| 2024-05-20 | 33.4 | 2024-03-13 | 24.1 |
| 2024-05-17 | 32.8 | 2024-03-12 | 23.6 |
| 2024-05-16 | 32.6 | 2024-03-11 | 24.3 |
| 2024-05-15 | 32.6 | 2024-03-08 | 23.9 |
| 2024-05-14 | 32.1 | 2024-03-07 | 24.3 |
| 2024-05-13 | 32.1 | 2024-03-06 | 23.2 |
| 2024-05-10 | 31.8 | 2024-03-05 | 23.2 |
| 2024-05-09 | 31.0 | 2024-03-04 | 23.2 |
| 2024-05-08 | 30.9 | 2024-03-01 | 23.2 |
| 2024-05-07 | 31.5 | 2024-02-29 | 22.8 |
| 2024-05-06 | 32.1 | 2024-02-28 | 21.9 |
| 2024-05-03 | 31.5 | 2024-02-27 | 20.8 |
| 2024-05-02 | 31.3 | 2024-02-26 | 22.0 |
| 2024-04-30 | 32.0 | 2024-02-23 | 21.9 |
| 2024-04-29 | 31.4 | 2024-02-22 | 22.1 |
| 2024-04-26 | 32.3 | 2024-02-21 | 21.8 |
| 2024-04-25 | 32.2 | 2024-02-20 | 21.8 |
| 2024-04-24 | 30.3 | 2024-02-19 | 21.8 |
| 2024-04-23 | 30.6 | 2024-02-16 | 21.6 |
| 2024-04-22 | 30.2 | 2024-02-15 | 21.3 |
| 2024-04-19 | 30.2 | 2024-02-14 | 21.3 |
| 2024-04-18 | 30.2 | 2024-02-13 | 21.0 |
| 2024-04-17 | 30.7 | 2024-02-12 | 20.8 |
| 2024-04-16 | 31.1 | 2024-02-09 | 20.9 |
| 2024-04-15 | 31.5 | 2024-02-08 | 20.5 |
| 2024-04-12 | 31.3 | 2024-02-07 | 20.4 |
| 2024-04-11 | 31.1 | 2024-02-06 | 20.0 |
| 2024-04-10 | 31.0 | 2024-02-05 | 20.1 |
| 2024-04-09 | 31.1 | 2024-02-02 | 19.4 |
| 2024-04-08 | 31.4 | 2024-02-01 | 19.5 |
| 2024-04-05 | 31.1 | 2024-01-31 | 19.7 |
| 2024-04-04 | 30.7 | 2024-01-30 | 19.5 |
| 2024-04-03 | 30.3 | 2024-01-29 | 18.9 |
| 2024-04-02 | 31.2 | 2024-01-26 | 20.0 |
Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Laboratorios Farmaceuticos Rovi SA
ISIN : ES0157261019
Share Class Description:
XMAD:ROVI: Ordinary SharesCompare
Compare
Traded in other countries / regions
ROVI.Spain0ILL.UKROVI.MexicoROVI.Austria41L.GermanyLABFF.USA IPO Date
2007-10-26Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers